Sandra Lee

Dr. Sandra Lee


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2018 in The American Journal of Bioethics
Verified
Journal Article
Closed access
SKStephanie A. Kraft
Stephanie A. Kraft
MCMildred K. Cho
Mildred K. Cho
KGKatherine Gillespie
Katherine Gillespie
MHMeghan Halley
Meghan Halley
NVNina Varsava
Nina Varsava
SLSandra Lee
Sandra Lee
With the growth of precision medicine research on health data and biospecimens, research institutions will need to build and maintain long-term, trusting relationships with patient-participants. While trust is important for all research relationships, the longitudinal nature of precision medicine research raises particular challenges for facilitating trust when the specifics of future studies are unknown. Based on focus groups with racially and ethnically diverse patients, we describe several factors that influence patient trust and potential institutional approaches to building trustworthiness. Drawing on these findings, we suggest several considerations for research institutions seeking to cultivate long-term, trusting relationships with patients: (1) Address the role of history and experience on trust, (2) engage concerns about potential group harm, (3) address cultural values and communication barriers, and (4) integrate patient values and expectations into oversight and governance structures.

11 June 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
SLSandra Lee
Sandra Lee
MCMildred K. Cho
Mildred K. Cho
SKStephanie A. Kraft
Stephanie A. Kraft
NVNina Varsava
Nina Varsava
KGKatie Gillespie
Katie Gillespie
DMDavid Magnus
David Magnus

25 August 2015 in The American Journal of Bioethics
Verified
Journal Article
Closed access
MKMaureen Kelley
Maureen Kelley
CJCyan James
Cyan James
SKStephanie Alessi Kraft
Stephanie Alessi Kraft
DKDiane Korngiebel
Diane Korngiebel
IWIsabelle Wijangco
Isabelle Wijangco
SLSandra Lee
Sandra Lee
We conducted focus groups to assess patient attitudes toward research on medical practices in the context of usual care. We found that patients focus on the implications of this research for their relationship with and trust in their physicians. Patients view research on medical practices as separate from usual care, demanding dissemination of information and in most cases, individual consent. Patients expect information about this research to come through their physician, whom they rely on to identify and filter associated risks. In general, patients support this research, but worry that participation in research involving randomization may undermine individualized care that acknowledges their unique medical histories. These findings suggest the need for public education on variation in practice among physicians and the need for a collaborative approach to the governance of research on medical practices that addresses core values of trust, transparency, and partnership.

1 January 2008 in Genome Biology
Verified
Journal Article
Open access
PDF file
SLSandra Lee
Sandra Lee
JMJoanna Mountain
Joanna Mountain
BKBarbara Koenig
Barbara Koenig
RARuss Altman
Russ Altman
MBMelissa Brown
Melissa Brown
PUPeter Underhill
Peter Underhill
We are a multidisciplinary group of Stanford faculty who propose ten principles to guide the use of racial and ethnic categories when characterizing group differences in research into human genetic variation.

1 December 2005 in American Journal of Public Health
Verified
Journal Article
Closed access
SLSandra Lee
Sandra Lee
Current practices of using “race” in pharmacogenomics research demands consideration of the ethical and social implications for understandings of group difference and for efforts to eliminate health disparities. This discussion focuses on an “infrastructure of racialization” created by current trajectories of research on genetic differences among racially identified groups, the use of race as a proxy for risk in clinical practice, and increasing interest in new market niches by the pharmaceutical industry. The confluence of these factors has resulted in the conflation of genes, disease, and race. I argue that public investment in pharmacogenomics requires careful consideration of current inequities in health status and social and ethical concerns over reifying race and issues of distributive justice.

1 April 2016 in Social Science & Medicine
Verified
Journal Article
Closed access
KDKatherine Weatherford Darling
Katherine Weatherford Darling
SASara L. Ackerman
Sara L. Ackerman
RHRobert H. Hiatt
Robert H. Hiatt
SLSandra Lee
Sandra Lee
JSJanet K. Shim
Janet K. Shim